Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pro-Pharmaceuticals Selects Camargo for Regulatory Support | Contract Pharma

What are you searching for?

Sign in
Breaking News

Pro-Pharmaceuticals Selects Camargo for Regulatory Support

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pro-Pharmaceuticals, Inc. has retained Camargo Pharmaceutical Services to provide strategic regulatory support for the company’s 505(b)(2) submissions for Davanat with the FDA. Camargo’s regulatory support includes the preparation and submission of NDAs, aNDAs, and 505(b)(2) NDAs to help expedite the regulatory submission and approval process for clients.

“Our goal is to get Davanat to market in a timely manner with multiple chemotherapy drugs,” stated David Platt, Ph.D., chief executive officer, Pro-Pharmaceuticals, Inc. “We submitted pre-clinical and clinical data to the FDA that demonstrates Davanat improves 5-FU. In other preclinical studies, Davanat also improved activity of FDA-approved chemotherapeutics, such as Irinotecan, Oxaliplatin, Cisplatin, Avastin, Taxol and Doxorubicin.”

The company has submitted data to begin 505(b)(2) filings for Davanat as a functional excipient to be co-administered intravenously with 5-FU to treat cancer. The functional excipients are important as a drug target delivery to reduce toxicity and/or increase efficacy.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics